Pharmasset’s PSI-7977 is one of the hottest drugs now in development for hepatitis C. And the biotech burnished its rep this morning by restructuring its clinical program for the treatment, adding one arm which will study the drug as a single treatment…

The rich deal in which PPD was purchased by two private equity firms for $3.9 billion underscores just how attractive CROs can be right now. But why? For one thing, they keep raising prices.

A Cheektowaga nonprofit group has won a federal contract worth up to $36 million over five years to develop a drug to treat respiratory disease caused by…

“We hired a new CEO, but had to let him go after just seven months,” the chairman of an East Coast think tank complained to me recently. “His resume looked spectacular, he did splendidly in all the interviews. But within a week or two we were hearing…

There’s a misconception that the most successful business leaders achieve greatness because they’re insanely smart—geniuses, even. You look at people like Mark Zuckerberg, Reed Hastings, and Warren Buffett, and it seems that might just be true.